SuperworthVanda Pharmaceuticals profit margin VNDA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- n/m
- not a meaningful number
- Operating margin, 12 months
- −86.1%
- Peer median
- 13.6%
Vanda Pharmaceuticals' net margin works out at −127% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | −70.0% | 94.0% |
| FY2024 | −9.5% | −20.5% | 94.3% |
| FY2023 | 1.3% | −7.2% | 92.3% |
| FY2022 | 2.5% | 2.5% | 90.5% |
| FY2021 | 12.3% | 15.7% | 90.5% |
| FY2020 | 9.4% | 11.0% | 90.6% |
| FY2019 | 50.9% | 10.0% | 89.2% |
| FY2018 | 13.1% | 11.3% | 89.4% |
| FY2017 | −9.4% | −10.2% | 89.2% |
| FY2016 | −12.3% | −12.7% | 83.1% |
| FY2015 | −36.3% | −36.6% | 78.7% |
| FY2014 | 40.2% | 40.0% | n/a |
| FY2013 | −62.1% | −62.6% | n/a |
| FY2012 | −84.5% | −86.2% | n/a |
| FY2011 | −31.3% | −34.2% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | −86.1% | |
| Q1 FY26 | n/a | n/a | −73.6% | |
| Q4 FY25 | n/a | n/a | −70.0% | |
| Q3 FY25 | −39.7% | −31.1 pts | −57.1% | |
| Q2 FY25 | −32.9% | −26.9 pts | −49.5% | |
| Q1 FY25 | −22.0% | −19.2 pts | −36.0% | |
| Q4 FY24 | −9.5% | −10.8 pts | −20.5% | |
| Q3 FY24 | −8.6% | −14.1 pts | −19.6% | |
| Q2 FY24 | −6.0% | −12.3 pts | −17.8% | |
| Q1 FY24 | −2.8% | −9.0 pts | −14.2% | |
| Q4 FY23 | 1.3% | −1.2 pts | −7.2% | |
| Q3 FY23 | 5.6% | +3.0 pts | −0.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| VNDAVanda Pharmaceuticals | n/m |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| LFVNLifevantage | 2.8% |
| ABUSArbutus Biopharma | 84.2% |
| SPROSpero Therapeutics | 15.7% |
| Peer median | 13.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Vanda Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.